HC Wainwright & Co. Reiterates Buy on Mind Medicine, Maintains $35 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Mind Medicine (NASDAQ:MNMD) and maintained a $35 price target.
July 31, 2024 | 12:11 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Mind Medicine and maintained a $35 price target, indicating strong confidence in the company's future performance.
The reiteration of a Buy rating and a high price target by a reputable analyst firm like HC Wainwright & Co. is likely to boost investor confidence in Mind Medicine, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100